Although news came out that it had succeeded in developing a new drug for hair loss in the United States, it was confirmed that it was not a treatment for ‘male pattern baldness’ that most people with hair loss suffer from, but rather a treatment for ‘circular hair loss’, which is considered one of the autoimmune diseases. Alopecia areata is a disease that is already being treated with steroids and immunomodulators.
According to the biopharmaceutical industry on the 27th, Concert Pharmaceuticals in Lexington, Massachusetts, USA, recently conducted a phase 3a clinical trial of ‘CTP-543’, an oral new drug candidate, for adult patients suffering from moderate to severe alopecia areata. Result He said that he confirmed the positive topline result.
Shares of some companies such as HK Innoen (195940) soared on the news of the successful clinical trial of a new hair loss drug from the US. As CTP-543, which is being developed by Concert Pharmaceuticals, became known as a method of treating hair loss by inhibiting the enzymes JAK1 and JAK2 that are activated during the immune response, HK Innoen, which has a new drug candidate for JAK, seems to have received attention.
CTP-543, which is being developed by Concert Pharmaceuticals, has been confirmed as a new drug candidate to treat alopecia areata rather than to treat male pattern hair loss that most people suffer from.
According to the Korea Centers for Disease Control and Prevention, alopecia areata is an inflammatory disease that invades hair follicles. It is a non-scarring autoimmune hair loss disease that is characterized by circular bald spots and can invade the hair or all hairs of the human body.
Treatment for alopecia areata is already being done. According to Seoul National University Bundang Hospital, alopecia areata is treated with oral steroids alone, topical application, or intralesional injection for 4 to 8 weeks. There is also a way to take immunosuppressive and modulators such as cyclosporine for weeks to months.
Androgenetic alopecia, which is known to occur in about half of all men after the age of 50, is a disease that can be caused by hormones and mainly occurs in men with a genetic predisposition. Testosterone, a male hormone, is converted into a hormonal substance called DHT by 5-alpha reductase in hair follicles. These hormones cause hair loss.
For androgenetic alopecia, oral medications such as finasteride or dutasteride and topical minoxidil are used to alleviate the symptoms. When a treatment for hair growth in androgenetic alopecia is developed, the market will be great, but the new drug or treatment has not yet been developed.
Meanwhile, Concert Pharmaceuticals conducted a phase 3a clinical trial for 706 patients with moderate to severe alopecia areata between the ages of 18 and 65 in the United States, Canada, and Europe for the past 6 months.
Participants who had only 16% of their hair remaining at the start of the study were divided into three groups: a placebo group, an 8 mg tablet twice a day group, and a 12 mg tablet twice a day.
As a result of the test, hair regrowth in both groups given the pills. The hair regeneration rate of 41.5% of the group taking the high dose was 80%. 30% of the group administered with the lower dose also succeeded in regenerating 80% of the hair. The research team explained that less than 5% of patients complained of side effects, and only mild symptoms such as headache and acne were seen.
Send articles on social media